Cargando…

Time to Recurrence and Survival in Serous Ovarian Tumors Predicted from Integrated Genomic Profiles

BACKGROUND: Serous ovarian cancer (SeOvCa) is an aggressive disease with differential and often inadequate therapeutic outcome after standard treatment. The Cancer Genome Atlas (TCGA) has provided rich molecular and genetic profiles from hundreds of primary surgical samples. These profiles confirm m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mankoo, Parminder K., Shen, Ronglai, Schultz, Nikolaus, Levine, Douglas A., Sander, Chris
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3207809/ https://www.ncbi.nlm.nih.gov/pubmed/22073136 http://dx.doi.org/10.1371/journal.pone.0024709

Ejemplares similares

Integrated Analyses of microRNAs Demonstrate Their Widespread Influence on Gene Expression in High-Grade Serous Ovarian Carcinoma
por: Creighton, Chad J., et al.
Publicado: (2012)

Integrative Subtype Discovery in Glioblastoma Using iCluster
por: Shen, Ronglai, et al.
Publicado: (2012)

Evaluating cell lines as tumour models by comparison of genomic profiles
por: Domcke, Silvia, et al.
Publicado: (2013)

Integrated Multi-Tumor Radio-Genomic Marker of Outcomes in Patients with High Serous Ovarian Carcinoma
por: Veeraraghavan, Harini, et al.
Publicado: (2020)

Isolated recurrence of ovarian serous adenocarcinoma to adrenal gland
por: Borczuk, Rachel, et al.
Publicado: (2022)

Study design and data analysis considerations for the discovery of prognostic molecular biomarkers: a case study of progression free survival in advanced serous ovarian cancer
por: Qin, Li-Xuan, et al.
Publicado: (2016)

Integrating biological pathways and genomic profiles with ChiBE 2
por: Babur, Özgün, et al.
Publicado: (2014)

Both fallopian tube and ovarian surface epithelium are cells-of-origin for high-grade serous ovarian carcinoma
por: Zhang, Shuang, et al.
Publicado: (2019)

Hormone receptor expression profiles differ between primary and recurrent high-grade serous ovarian cancers
por: Feng, Zheng, et al.
Publicado: (2017)

Tumor Growth Rate Estimates Are Independently Predictive of Therapy Response and Survival in Recurrent High-Grade Serous Ovarian Cancer Patients
por: Bartl, Thomas, et al.
Publicado: (2021)

Integrated Analysis of Gene Expression and Tumor Nuclear Image Profiles Associated with Chemotherapy Response in Serous Ovarian Carcinoma
por: Liu, Yuexin, et al.
Publicado: (2012)

Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma
por: Ducie, Jennifer, et al.
Publicado: (2017)

Proteome profiling of low grade serous ovarian cancer
por: zadeh fakhar, Haniyeh Bashi, et al.
Publicado: (2019)

MDCT-Based Radiomics Features for the Differentiation of Serous Borderline Ovarian Tumors and Serous Malignant Ovarian Tumors
por: Yu, Xin-ping, et al.
Publicado: (2021)

A pan-cancer survey of cell line tumor similarity by feature-weighted molecular profiles
por: Sinha, Rileen, et al.
Publicado: (2021)

Testing for NRAS Mutations in Serous Borderline Ovarian Tumors and Low-Grade Serous Ovarian Carcinomas
por: Sadlecki, Pawel, et al.
Publicado: (2018)

Identification of clinical and molecular features of recurrent serous borderline ovarian tumour
por: Lu, Ziyang, et al.
Publicado: (2022)

Serum Protein Profile at Remission Can Accurately Assess Therapeutic Outcomes and Survival for Serous Ovarian Cancer
por: Wang, Jinhua, et al.
Publicado: (2013)

Mitochondrial mRNA transcripts predict overall survival, tumor recurrence and progression in serous ovarian cancer: Companion diagnostics for cancer therapy
por: Sotgia, Federica, et al.
Publicado: (2017)

Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling
por: Santin, A D, et al.
Publicado: (2004)

Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer
por: Létourneau, Isabelle J, et al.
Publicado: (2012)

Endosalpingiosis in Conjunction with Ovarian Serous Cystadenoma Mimicking Metastatic Ovarian Malignancy
por: Singhania, Namrata, et al.
Publicado: (2014)

Gene Expression Profile for Predicting Survival in Advanced-Stage Serous Ovarian Cancer Across Two Independent Datasets
por: Yoshihara, Kosuke, et al.
Publicado: (2010)

Unsupervised analysis reveals two molecular subgroups of serous ovarian cancer with distinct gene expression profiles and survival
por: Lisowska, Katarzyna M., et al.
Publicado: (2016)

DNA methylation-based profiling reveals distinct clusters with survival heterogeneity in high-grade serous ovarian cancer
por: Wang, Jieyu, et al.
Publicado: (2021)

Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance
por: Ricciardelli, Carmela, et al.
Publicado: (2017)

The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma
por: Smith, Philip, et al.
Publicado: (2023)

Expression and molecular profiles of the AlkB family in ovarian serous carcinoma
por: Cai, Yuan, et al.
Publicado: (2021)

High Levels of Genomic Aberrations in Serous Ovarian Cancers Are Associated with Better Survival
por: Baumbusch, Lars O., et al.
Publicado: (2013)

The AgNORs count in predicting long-term survival in serous ovarian cancer
por: Gottwald, Leszek, et al.
Publicado: (2013)

Association of Copy Number Variation Signature and Survival in Patients With Serous Ovarian Cancer
por: Graf, Ryon P., et al.
Publicado: (2021)

Development of Low-Grade Serous Ovarian Carcinoma from Benign Ovarian Serous Cystadenoma Cells
por: Dey, Puja, et al.
Publicado: (2022)

MRI appearance of ovarian serous borderline tumors of the micropapillary type compared to that of typical ovarian serous borderline tumors: radiologic-pathologic correlation
por: Nakai, Go, et al.
Publicado: (2018)

MODY5 and Serous Ovarian Carcinoma in 17q12 Recurrent Deletion Syndrome
por: Kumar, Aswathi, et al.
Publicado: (2023)

A long-term surviving patient with recurrent low-grade serous ovarian carcinoma treated with the MEK1/2 inhibitor, selumetinib
por: Takekuma, Munetaka, et al.
Publicado: (2016)

CCNE1 and survival of patients with tubo‐ovarian high‐grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study
por: Kang, Eun‐Young, et al.
Publicado: (2022)

Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors
por: Ouellet, Véronique, et al.
Publicado: (2008)

The Tumor Microenvironment of High Grade Serous Ovarian Cancer
por: Stack, M. Sharon, et al.
Publicado: (2018)

Histopathological Patterns of Microinvasion in Ovarian Serous Borderline Tumors
por: CÎRSTEA, A.E., et al.
Publicado: (2018)

EGFR Immunoexpression in Malignant Serous and Mucinous Ovarian Tumors
por: CÎRSTEA, A.E., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5jdd0b0tns92c7qf5aidunqv20